PROJECT ALIX LIMITED

Financial Health Score: B-

Explanation: Project Alix Limited has received a financial blood transfusion that has pulled it back from the brink of insolvency, transforming a critically ill balance sheet into one with a healthy cash pulse. However, the underlying business metabolism is still burning through cash rather than generating it. The overall grade reflects excellent short-term liquidity but significant concerns regarding long-term operational profitability.

1. Key Vital Signs

• Pulse (Cash Position): £413,762 The patient’s pulse is incredibly strong compared to the prior year (£17,870). This massive influx of cash ensures the company has an immediate runway to operate and survive.
• Blood Pressure (Net Assets): £430,401 Previously in negative equity (-£56,293), the company's net assets have stabilized into positive territory. This indicates the business is no longer technically insolvent and can cover its debts if they fell due today.
• Cholesterol (Current Liabilities): £12,154 Down significantly from £84,163. A major blockage—the £80,000 owed to "Zinc"—has been cleared, drastically reducing the financial strain on the company's short-term obligations.
• Metabolism (Profit & Loss Reserve): -£191,077 This is the concerning vital sign. The P&L reserve has deepened from -£56,393 to -£191,077, indicating an operating loss of roughly £134,684 for the year. The business is still consuming more energy (cash) than it is generating through operations.

2. Diagnosis

The Patient has Stabilized, but the Underlying Illness Remains

Looking at the clinical history, Project Alix Limited was in severe financial distress at the end of September 2024. It had negative net assets, minimal cash, and a large, looming creditor (Zinc) that likely threatened its survival.

However, the 2025 accounts show the signs of a miraculous recovery—driven almost entirely by an external intervention. The company received a substantial capital injection via a Share Premium account (£621,348). Think of this as an emergency blood transfusion: it immediately replenished the company's depleted cash reserves and provided the funds to clear the toxic debt (Zinc).

Yet, while the balance sheet looks robust on the surface, the P&L reserve tells a story of ongoing internal bleeding. The core business activities (classified under "Other business support service activities") are not generating positive cash flow; rather, they are burning through the newly invested capital at a rate of over £134,000 a year. The company is currently kept alive by the funds raised from its shareholders, not by its own operational pulse.

3. Prognosis

Stable in the Short Term, Guarded in the Long Term

In the immediate future, the prognosis is excellent. With over £413,000 in the bank and only £12,154 in current liabilities, the company has a robust cash runway. If the current burn rate of ~£134,000 per year remains static, the company has roughly three years of operating life left before it requires another intervention.

However, if the operational losses are not addressed, the financial health will inevitably deteriorate back to a critical state once the cash transfusion runs out. The transition from a deeply loss-making venture to a self-sustaining business is the critical hurdle ahead.

4. Recommendations

1. Stop the Internal Bleeding (Revenue Generation): Management must focus on converting the business support services into profitable revenue. The £621k investment was meant to fund growth and operations, not to be slowly bled out without a return.
2. Monitor the Cash Burn Rate: Conduct monthly "check-ups" on cash flow. At a £134k annual burn, the runway is finite. If revenues do not begin to offset costs within the next 12-18 months, drastic cost-cutting measures must be taken to preserve the remaining £413k.
3. Re-evaluate the Deposit Asset: The accounts show a £9,600 "Deposit" with Gravitas Recruitment Group. Ensure this deposit is recoverable or serves a strategic purpose, as tied-up capital does not contribute to daily operational health.
4. Prepare for Future Funding: Given the early-stage nature of the company (incorporated in 2023) and the reliance on share premium for survival, directors should start laying the groundwork for future funding rounds or a clear path to profitability before the current cash reserves are depleted.